This newest twist during the Lykos Therapeutics saga threatens a major overhaul of the organization’s strategy and path, with Musk ally and billionaire investor Antonio Gracias showing to choose to take the organization back again toward its nonprofit drug advancement roots and a far more Doblinite philosophy.Patent apps are mystery for eighteen